Hanchen Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hanchen Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Jean Marie Houghton
5 shared publications- Jian Hua Liu
Division of Gastroenterology, Department of Medicine, University of Massachusetts Medical School, Worcester, USA
5 shared publications - Calin Stoicov
Division of Gastroenterology, Department of Medicine, University of Massachusetts Medical School, Worcester, USA
4 shared publications - Ernesto R. Soto
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
2 shared publications - Florentina Rus
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
2 shared publications - Gary R. Ostroff
Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA
2 shared publications
Latest Publications
- Open Access
Yeast Particle Encapsulation of Scaffolded Terpene Compounds for Controlled Terpene Release
Terpenes are naturally occurring compounds produced by plants that are of great commercial interest in the food, agricultural, cosmetic, and pharmaceutical industries due to their broad spectra of antibacterial, antifungal, anthelmintic, membrane permeation enhancement, and antioxidant biological activities. Applications of terpenes are often limited by their volatility and the need for surfactants or alcohols to produce stable, soluble (non-precipitated) products. Yeast particles (YPs) are hollow, porous microspheres that have been used for the encapsulation of terpenes (YP terpenes) by passive diffusion of terpenes through the porous YP cell walls. We here report the development of a second generation YP encapsulated terpene technology that incorporates the stimuli-responsive control of terpene release using biodegradable pro-terpene compounds (YP pro-terpenes). YP terpenes and YP pro-terpenes were both produced, in which high levels of carvacrol, eugenol, thymol and geraniol were encapsulated. The YP pro-terpenes show higher encapsulation stability than YP terpenes due to pro-terpenes being non-volatile solids at room temperature and stable in suspensions at neutral pH. YP pro-terpenes and YP terpenes were evaluated for biological activity in antibacterial, antifungal and anthelmintic assays. The YP pro-terpenes retained the full biological activity of the parent terpene compound.
Open AccessYeast Particle Encapsulation of Scaffolded Terpene Compounds for Controlled Terpene Release
Terpenes are naturally occurring compounds produced by plants that are of great commercial interest in the food, agricultural, cosmetic, and pharmaceutical industries due to their broad spectra of antibacterial, antifungal, anthelmintic, membrane permeation enhancement, and antioxidant biological activities. Applications of terpenes are often limited by their volatility and the need for surfactants or alcohols to produce stable, soluble (non-precipitated) products. Yeast particles (YPs) are hollow, porous microspheres that have been used for the encapsulation of terpenes (YP terpenes) by passive diffusion of terpenes through the porous YP cell walls. We here report the development of a second generation YP encapsulated terpene technology that incorporates the stimuli-responsive control of terpene release using biodegradable pro-terpene compounds (YP pro-terpenes). YP terpenes and YP pro-terpenes were both produced, in which high levels of carvacrol, eugenol, thymol and geraniol were encapsulated. The YP pro-terpenes show higher encapsulation stability than YP terpenes due to pro-terpenes being non-volatile solids at room temperature and stable in suspensions at neutral pH. YP pro-terpenes and YP terpenes were evaluated for biological activity in antibacterial, antifungal and anthelmintic assays. The YP pro-terpenes retained the full biological activity of the parent terpene compound.
- Open Access
Recombinant Paraprobiotics as a New Paradigm for Treating Gastrointestinal Nematode Parasites of Humans
Gastrointestinal nematodes (GINs) of humans, e.g ., hookworms, negatively impact childhood growth, cognition, nutrition, educational attainment, income, productivity, and pregnancy. Hundreds of millions of people are targeted with mass drug administration (MDA) of donated benzimidazole (BZ) anthelmintics. However, BZ efficacy against GINs is suboptimal, and reduced/low efficacy has been seen. Developing an anthelmintic for human MDA is daunting: it must be safe, effective, inexpensive, stable without a cold chain, and massively scalable. Bacillus thuringiensis (Bt) crystal protein 5B (Cry5B) has anthelmintic properties that could fill this void. Here we develop an API (Active Pharmaceutical Ingredient) form of Bt Cry5B compatible with MDA. We expressed Cry5B in asporogenous Bt during vegetative phase, forming cytosolic crystals. These Ba cteria with C ytosolic C rystals (BaCC) were rendered inviable (inactivated BaCC or IBaCC) with food-grade essential oils. IBaCC potency was validated in vitro against nematodes. IBaCC was also potent in vivo against human hookworm infections in hamsters. IBaCC production was successfully scaled to 350 liters at a contract manufacturing facility. A simple fit-for-purpose formulation to protect against stomach digestion and powdered IBaCC were successfully made and used against GINS in hamsters and mice. A pilot histopathology study and blood chemistry workup showed that five daily consecutive doses of 200 mg/kg Cry5B IBaCC (the curative single dose is 40 mg/kg) was non-toxic and completely safe. IBaCC is a safe, inexpensive, highly effective, easy-to-manufacture, and scalable anthelmintic that is practical for MDA and represents a new paradigm for treating human GINs.
Open AccessRecombinant Paraprobiotics as a New Paradigm for Treating Gastrointestinal Nematode Parasites of Humans
Gastrointestinal nematodes (GINs) of humans, e.g ., hookworms, negatively impact childhood growth, cognition, nutrition, educational attainment, income, productivity, and pregnancy. Hundreds of millions of people are targeted with mass drug administration (MDA) of donated benzimidazole (BZ) anthelmintics. However, BZ efficacy against GINs is suboptimal, and reduced/low efficacy has been seen. Developing an anthelmintic for human MDA is daunting: it must be safe, effective, inexpensive, stable without a cold chain, and massively scalable. Bacillus thuringiensis (Bt) crystal protein 5B (Cry5B) has anthelmintic properties that could fill this void. Here we develop an API (Active Pharmaceutical Ingredient) form of Bt Cry5B compatible with MDA. We expressed Cry5B in asporogenous Bt during vegetative phase, forming cytosolic crystals. These Ba cteria with C ytosolic C rystals (BaCC) were rendered inviable (inactivated BaCC or IBaCC) with food-grade essential oils. IBaCC potency was validated in vitro against nematodes. IBaCC was also potent in vivo against human hookworm infections in hamsters. IBaCC production was successfully scaled to 350 liters at a contract manufacturing facility. A simple fit-for-purpose formulation to protect against stomach digestion and powdered IBaCC were successfully made and used against GINS in hamsters and mice. A pilot histopathology study and blood chemistry workup showed that five daily consecutive doses of 200 mg/kg Cry5B IBaCC (the curative single dose is 40 mg/kg) was non-toxic and completely safe. IBaCC is a safe, inexpensive, highly effective, easy-to-manufacture, and scalable anthelmintic that is practical for MDA and represents a new paradigm for treating human GINs.
- Open Access
- 20 July 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (9) , 2466-2477
Mesenchymal Stem Cells Utilize CXCR4–SDF-1 Signaling for Acute, but Not Chronic, Trafficking to Gastric Mucosal Inflammation
Background Helicobacter infection is the main risk factor in developing gastric cancer. Mesenchymal stem cells (MSCs) are non-hematopoietic stromal cells, which are able to differentiate into different cell lineages. MSC contribute to cancer development by forming the tumor directly, contributing to the microenvironment, or by promoting angiogenesis and metastasis. CXCR4/SDF-1 axis is used by MSC in trafficking, homing, and engraftment at chronic inflammation sites, and plays an important role in tumorigenesis. Aim To determine if CXCR4 receptor has a role in MSC contribution to the development of Helicobacter-mediated gastric cancer. Methods SDF-1 and CXCR4 expression in mouse gastric mucosa in the setting of acute and chronic inflammation was measured using RT-PCR. Mouse culture-adapted MSC express CXCR4. Wild-type C57BL/6 mice infected with Helicobacter felis for 6 months or controls were given IV injections of CXCR4 knock-down MSC. Animals were followed for another 4 months. Homing of MSC in the stomach was quantified using RT-PCR. MSC differentiation into gastric epithelia lineages was analyzed using immunohistochemistry and fluorescent in situ hybridization. Results CXCR4 and SDF-1 are both upregulated in the settings of Helicobacter-induced chronic gastric inflammation. CXCR4 is fully required for homing of MSC to the stomach in acute gastric inflammation, but only partially in Helicobacter-induced gastric cancer. MSC lead to gastric intraepithelial neoplasia as early as 10 months of Helicobacter infection. Conclusions Our results show that MSC have a tumorigenic effect by promoting an accelerated form of gastric cancer in mice. The engraftment of MSC in chronic inflammation is only partially CXCR4-dependent.
- 20 July 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (9) , 2466-2477
Open AccessMesenchymal Stem Cells Utilize CXCR4–SDF-1 Signaling for Acute, but Not Chronic, Trafficking to Gastric Mucosal Inflammation
Background Helicobacter infection is the main risk factor in developing gastric cancer. Mesenchymal stem cells (MSCs) are non-hematopoietic stromal cells, which are able to differentiate into different cell lineages. MSC contribute to cancer development by forming the tumor directly, contributing to the microenvironment, or by promoting angiogenesis and metastasis. CXCR4/SDF-1 axis is used by MSC in trafficking, homing, and engraftment at chronic inflammation sites, and plays an important role in tumorigenesis. Aim To determine if CXCR4 receptor has a role in MSC contribution to the development of Helicobacter-mediated gastric cancer. Methods SDF-1 and CXCR4 expression in mouse gastric mucosa in the setting of acute and chronic inflammation was measured using RT-PCR. Mouse culture-adapted MSC express CXCR4. Wild-type C57BL/6 mice infected with Helicobacter felis for 6 months or controls were given IV injections of CXCR4 knock-down MSC. Animals were followed for another 4 months. Homing of MSC in the stomach was quantified using RT-PCR. MSC differentiation into gastric epithelia lineages was analyzed using immunohistochemistry and fluorescent in situ hybridization. Results CXCR4 and SDF-1 are both upregulated in the settings of Helicobacter-induced chronic gastric inflammation. CXCR4 is fully required for homing of MSC to the stomach in acute gastric inflammation, but only partially in Helicobacter-induced gastric cancer. MSC lead to gastric intraepithelial neoplasia as early as 10 months of Helicobacter infection. Conclusions Our results show that MSC have a tumorigenic effect by promoting an accelerated form of gastric cancer in mice. The engraftment of MSC in chronic inflammation is only partially CXCR4-dependent.
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
238 In Vitro Transformation of Gastric Epithelial Cells Through Fusion With Mesenchymal Stem Cells
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
238 In Vitro Transformation of Gastric Epithelial Cells Through Fusion With Mesenchymal Stem Cells
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Helicobacter Infection and Gastric Cancer – Migration of MSC in Response to SDF-1/CXCR4 Signaling
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Helicobacter Infection and Gastric Cancer – Migration of MSC in Response to SDF-1/CXCR4 Signaling
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
CD95 Signaling Induces EMT in Colon Cancer Cells
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
CD95 Signaling Induces EMT in Colon Cancer Cells
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , A-791-791
85 Cultured Mouse Menchymal Stem Cells Form Hepatocytes By FUSION with Host Hepatocytes and Directly Contribute to Sinusoidal Cells By Transdifferentiation
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , A-791-791
85 Cultured Mouse Menchymal Stem Cells Form Hepatocytes By FUSION with Host Hepatocytes and Directly Contribute to Sinusoidal Cells By Transdifferentiation
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
57 Bone Marrow Derived Cells Contribute to the Tumor Microenvironment and Increase the Aggressiveness of Colon Cancer Cells
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
57 Bone Marrow Derived Cells Contribute to the Tumor Microenvironment and Increase the Aggressiveness of Colon Cancer Cells